Liminatus Pharma, Inc. Class A Common Stock

LIMN · NASDAQ
Analyze with AI
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Operating Activities
Net Income-$2,904-$4,984-$2,928$4,370
Dep. & Amort.$0$0$0$0
Deferred Tax$0$0$0$0
Stock-Based Comp.$0$0$0$0
Change in WC-$45$1,639$1,159$1,318
Other Non-Cash-$158$0$900-$6,904
Operating Cash Flow-$3,106-$3,345-$869-$1,216
Investing Activities
PP&E Inv.$0$0$0$0
Net Acquisitions$0$0$0$0
Inv. Purchases-$189-$121-$15,128-$276,000
Inv. Sales/Matur.$2,157$0$279,092$0
Other Inv. Act.$0-$698$0$0
Investing Cash Flow$1,968-$819$263,964-$276,000
Financing Activities
Debt Repay.$2,850-$450$2,417$0
Stock Issued$0$0$4,200$283,072
Stock Repurch.-$1,803-$10,657-$700$0
Dividends Paid$0$0$0$0
Other Fin. Act.$0$10,657$0-$5,520
Financing Cash Flow$1,047-$450$5,917$277,552
Forex Effect$739$0$0$0
Net Chg. in Cash$648-$4,614$5,048$336
Supplemental Information
Beg. Cash$156$5,048$336$0
End Cash$805$434$5,048$336
Free Cash Flow-$3,106-$3,345-$869-$1,216
Liminatus Pharma, Inc. Class A Common Stock (LIMN) Financial Statements & Key Stats | AlphaPilot